الصفحة الرئيسية>>Signaling Pathways>> Cell Cycle/Checkpoint>> Wee1>>PD 166285 dihydrochloride

PD 166285 dihydrochloride

رقم الكتالوجGC50045

PD 166285 ثنائي هيدروكلوريد ، ركيزة من P-gp ، هو مثبط WEE1 ومثبط Myt1 ضعيف بقيم IC50 24 و 72 نانومتر ، على التوالي. يعرض PD 166285 ثنائي هيدروكلوريد IC50 لـ 3.433 μ ؛ M لـ Chk1.

Products are for research use only. Not for human use. We do not sell to patients.

PD 166285 dihydrochloride التركيب الكيميائي

Cas No.: 212391-63-4

الحجم السعر المخزون الكميّة
1 mg
185٫00
متوفر
10 mg
397٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor β (PDGFRβ) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G2 checkpoint.

Panek et al (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J.Pharmacol.Exp.Ther. 283 1433 PMID:9400019 |Wang et al (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res. 61 8211 PMID:11719452 |Hashimoto et al (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6 292 PMID:17177986

مراجعات

Review for PD 166285 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD 166285 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.